BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TranXenoGen, Inc. (LS:TXN) Receives U.S. Notice Of Allowance For Patent Relating To Genetic Manipulation Of Male Germ Cells


10/19/2005 5:09:17 PM

SHREWSBURY, Mass., Dec. 1 /PRNewswire-FirstCall/ -- TranXenoGen, Inc. ("TranXenoGen") announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application relating to the genetic engineering of male germ cells for the production of transgenic animals. This Notice constitutes acceptance of the application and indicates impending issuance of the patent.

The Company is developing the technology, known as Gene-Testes Transfection, as an alternative method for the production of high value transgenic animals that is applicable to many species. The technique involves the introduction of a gene into the germ cells of the testes, which would then produce sperm containing the transgene. Consequently, breeding of the male would result in the transmission of the gene to the next generation and the production of a transgenic animal.

TranXenoGen intends to out-license the technology as well as utilizing it for its own applications in therapeutic protein manufacturing.

ENQUIRIES: TranXenoGen, Inc. Tel: 001 508 936 4214 George Uveges, President and CEO Email: guveges@tranxenogen.com College Hill Associates Tel: +44 (0) 7457 2020 Nicholas Nelson About TranXenoGen

TranXenoGen, Inc. (symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company is developing avian transgenic technologies for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.

Risk Warning Notice:

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

TranXenoGen, Inc.

CONTACT: George Uveges, President and CEO of TranXenoGen, Inc., 001 508936 4214, guveges@tranxenogen.com; or Nicholas Nelson of College HillAssociates, +44 (0) 7457 2020



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES